{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:49:28Z","timestamp":1792162168907,"version":"4.4.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The human microbiome has emerged as a critical modulator of cancer development, progression, and therapeutic response. Advances in sequencing and functional profiling have revealed that commensal microorganisms\u2014particularly bacteria\u2014interact closely with host immune and metabolic pathways, influencing tumor immunity across multiple cancer types. Dysbiosis of the gut microbiome has been associated with tumorigenesis, immune evasion, and resistance to therapy, while specific microbial taxa and metabolites have been shown to enhance antitumor immune responses. These discoveries have catalyzed the development of microbiome-based therapeutic strategies aimed at reshaping host\u2013tumor interactions. This review summarizes current understanding of the cancer\u2013microbiome axis, with a particular focus on therapeutic interventions that leverage microbial modulation. We discuss fecal microbiota transplantation (FMT) as an early, proof-of-concept approach demonstrating the capacity of the microbiome to restore responsiveness to immune checkpoint inhibitors, while also highlighting its limitations related to variability, standardization, and mechanistic uncertainty. We then examine emerging reductionist strategies, including supplementation with individual bacterial strains, defined consortia, and engineered microbes designed to deliver immunomodulatory payloads directly within the tumor microenvironment. Finally, we explore how microbial modulation interfaces with conventional cancer therapies such as chemotherapy, hormonal therapy, and cellular immunotherapies. Together, these studies illustrate a rapidly evolving field transitioning from correlative observations to mechanistically informed therapeutic design. While significant technical and biological challenges remain, continued integration of microbiology, immunology, and synthetic biology holds promise for translating microbiome-based interventions into safe, precise, and effective cancer therapies.<\/jats:p>","DOI":"10.1007\/s00281-026-01072-1","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:27:33Z","timestamp":1776346053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The cancer\u2013microbiome axis: Mechanisms and emerging therapeutic strategies"],"prefix":"10.1007","volume":"48","author":[{"given":"Maria Rae","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Schwarzfischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-1469","authenticated-orcid":false,"given":"Michael","family":"Scharl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"7758","key":"1072_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41586-019-1238-8","volume":"569","author":"LM Proctor","year":"2019","unstructured":"Proctor LM et al (2019) The Integrative human microbiome project. Nature 569(7758):641\u2013648. https:\/\/doi.org\/10.1038\/s41586-019-1238-8","journal-title":"Nature"},{"issue":"5","key":"1072_CR2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","volume":"71","author":"WM de Vos","year":"2022","unstructured":"de Vos WM, Tilg H, Van Hul M, Cani PD (2022) Gut microbiome and health: mechanistic insights. Gut 71(5):1020\u20131032. https:\/\/doi.org\/10.1136\/gutjnl-2021-326789","journal-title":"Gut"},{"issue":"1","key":"1072_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: New dimensions. Cancer Discov 12(1):31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"issue":"1","key":"1072_CR4","doi-asserted-by":"publisher","first-page":"7638","DOI":"10.1038\/s41467-025-62956-8","volume":"16","author":"B Tang","year":"2025","unstructured":"Tang B et al (2025) Cholecystectomy-related gut microbiota dysbiosis exacerbates colorectal tumorigenesis. Nat Commun 16(1):7638. https:\/\/doi.org\/10.1038\/s41467-025-62956-8","journal-title":"Nat Commun"},{"issue":"8","key":"1072_CR5","doi-asserted-by":"publisher","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","volume":"14","author":"R Sender","year":"2016","unstructured":"Sender R, Fuchs S, Milo R (2016) Revised estimates for the number of human and bacteria cells in the body. PLOS Biol 14(8):e1002533. https:\/\/doi.org\/10.1371\/journal.pbio.1002533","journal-title":"PLOS Biol"},{"issue":"4","key":"1072_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","volume":"70","author":"X Zhang","year":"2021","unstructured":"Zhang X et al (2021) Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 70(4):761\u2013774. https:\/\/doi.org\/10.1136\/gutjnl-2019-319664","journal-title":"Gut"},{"issue":"4","key":"1072_CR7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","volume":"33","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA (2018) The Influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 33(4):570\u2013580. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.015","journal-title":"Cancer Cell"},{"issue":"6","key":"1072_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41576-019-0113-7","volume":"20","author":"CY Chiu","year":"2019","unstructured":"Chiu CY, Miller SA (2019) Clinical metagenomics. Nat Rev Genet 20(6):341\u2013355. https:\/\/doi.org\/10.1038\/s41576-019-0113-7","journal-title":"Nat Rev Genet"},{"key":"1072_CR9","doi-asserted-by":"publisher","first-page":"1104707","DOI":"10.3389\/fmicb.2023.1104707","volume":"14","author":"PT Asare","year":"2023","unstructured":"Asare PT et al (2023) A MALDI-TOF MS library for rapid identification of human commensal gut bacteria from the class Clostridia. Front Microbiol 14:1104707. https:\/\/doi.org\/10.3389\/fmicb.2023.1104707","journal-title":"Front Microbiol"},{"key":"1072_CR10","doi-asserted-by":"publisher","first-page":"743923","DOI":"10.3389\/fchem.2021.743923","volume":"9","author":"SA Yoon","year":"2021","unstructured":"Yoon SA, Park SY, Cha Y, Gopala L, Lee MH (2021) Strategies of Detecting Bacteria Using Fluorescence-Based Dyes. Front Chem 9:743923. https:\/\/doi.org\/10.3389\/fchem.2021.743923","journal-title":"Front Chem"},{"key":"1072_CR11","doi-asserted-by":"publisher","first-page":"114727","DOI":"10.1016\/j.foodres.2024.114727","volume":"191","author":"J Wang","year":"2024","unstructured":"Wang J, Zheng Y, Huang H, Ma Y, Zhao X (2024) An overview of signal amplification strategies and construction methods on phage-based biosensors. Food Res Int Ott Ont 191:114727. https:\/\/doi.org\/10.1016\/j.foodres.2024.114727","journal-title":"Food Res Int Ott Ont"},{"issue":"4","key":"1072_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41568-023-00553-x","volume":"23","author":"S Bullman","year":"2023","unstructured":"Bullman S (2023) INVADEseq to study the intratumoural microbiota at host single-cell resolution. Nat Rev Cancer 23(4):189\u2013189. https:\/\/doi.org\/10.1038\/s41568-023-00553-x","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1072_CR13","doi-asserted-by":"publisher","first-page":"e00525","DOI":"10.1128\/mBio.00525-18","volume":"9","author":"PD Schloss","year":"2018","unstructured":"Schloss PD (2018) Identifying and overcoming threats to reproducibility, replicability, robustness, and generalizability in microbiome research. mBio 9(3):e00525\u2013e00518. https:\/\/doi.org\/10.1128\/mBio.00525-18","journal-title":"mBio"},{"issue":"5","key":"1072_CR14","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s13238-020-00813-8","volume":"12","author":"A Wong-Rolle","year":"2021","unstructured":"Wong-Rolle A, Wei HK, Zhao C, Jin C (2021) Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell 12(5):426\u2013435. https:\/\/doi.org\/10.1007\/s13238-020-00813-8","journal-title":"Protein Cell"},{"issue":"6494","key":"1072_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.aay9189","volume":"368","author":"D Nejman","year":"2020","unstructured":"Nejman D et al (2020) The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368(6494):973\u2013980. https:\/\/doi.org\/10.1126\/science.aay9189","journal-title":"Science"},{"issue":"10","key":"1072_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.ccell.2022.09.009","volume":"40","author":"B Ghaddar","year":"2022","unstructured":"Ghaddar B et al (2022) Tumor microbiome links cellular programs and immunity in pancreatic cancer. Cancer Cell 40(10):1240\u20131253.e5. https:\/\/doi.org\/10.1016\/j.ccell.2022.09.009","journal-title":"Cancer Cell"},{"issue":"8","key":"1072_CR17","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.cell.2022.02.027","volume":"185","author":"A Fu","year":"2022","unstructured":"Fu A et al (2022) Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell 185(8):1356\u20131372.e26 https:\/\/doi.org\/10.1016\/j.cell.2022.02.027","journal-title":"Cell"},{"issue":"6261","key":"1072_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1126\/science.aad2602","volume":"350","author":"KZ Coyte","year":"2015","unstructured":"Coyte KZ, Schluter J, Foster KR (2015) The ecology of the microbiome: Networks, competition, and stability. Science 350(6261):663\u2013666. https:\/\/doi.org\/10.1126\/science.aad2602","journal-title":"Science"},{"issue":"7921","key":"1072_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-022-04985-7","volume":"608","author":"M Bae","year":"2022","unstructured":"Bae M et al (2022) Akkermansia muciniphila phospholipid induces homeostatic immune responses. Nature 608(7921):168\u2013173. https:\/\/doi.org\/10.1038\/s41586-022-04985-7","journal-title":"Nature"},{"key":"1072_CR20","doi-asserted-by":"publisher","first-page":"1607543","DOI":"10.3389\/fimmu.2025.1607543","volume":"16","author":"L Bardouillet","year":"2025","unstructured":"Bardouillet L et al (2025) The gut microbiota protein BOC1 exhibits immune checkpoint inhibitor-like activity by inhibiting myeloid-derived suppressor cell differentiation. Front Immunol 16:1607543. https:\/\/doi.org\/10.3389\/fimmu.2025.1607543","journal-title":"Front Immunol"},{"issue":"3","key":"1072_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41564-023-01326-w","volume":"8","author":"Q Zhang","year":"2023","unstructured":"Zhang Q et al (2023) Genetic mapping of microbial and host traits reveals production of immunomodulatory lipids by Akkermansia muciniphila in the murine gut. Nat Microbiol 8(3):424\u2013440. https:\/\/doi.org\/10.1038\/s41564-023-01326-w","journal-title":"Nat Microbiol"},{"issue":"2","key":"1072_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","volume":"55","author":"K Hezaveh","year":"2022","unstructured":"Hezaveh K et al (2022) Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity 55(2):324\u2013340e. https:\/\/doi.org\/10.1016\/j.immuni.2022.01.006","journal-title":"Immunity"},{"issue":"23","key":"1072_CR23","doi-asserted-by":"publisher","first-page":"e140940","DOI":"10.1172\/jci.insight.140940","volume":"5","author":"A Limeta","year":"2020","unstructured":"Limeta A, Ji B, Levin M, Gatto F, Nielsen J (2020) Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight 5(23):e140940. https:\/\/doi.org\/10.1172\/jci.insight.140940","journal-title":"JCI Insight"},{"issue":"12","key":"1072_CR24","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.cell.2023.05.007","volume":"186","author":"CL Nguyen","year":"2023","unstructured":"Nguyen CL et al (2023) High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients. Cell 186(12):2705\u20132718 .e17, Jun. https:\/\/doi.org\/10.1016\/j.cell.2023.05.007","journal-title":"Cell"},{"issue":"10","key":"1072_CR25","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1055-9965.EPI-20-0288","volume":"29","author":"I Huybrechts","year":"2020","unstructured":"Huybrechts I et al (2020) The human microbiome in relation to cancer risk: a systematic review of epidemiological studies. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 29(10):1856\u20131868. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-0288","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"1072_CR26","doi-asserted-by":"publisher","unstructured":"Liou J-M et al (2025) Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II. Gut p. gutjnl-2025-336027. https:\/\/doi.org\/10.1136\/gutjnl-2025-336027","DOI":"10.1136\/gutjnl-2025-336027"},{"issue":"2","key":"1072_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L et al (2022) Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 28(2):315\u2013324. https:\/\/doi.org\/10.1038\/s41591-021-01655-5","journal-title":"Nat Med"},{"issue":"3","key":"1072_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","volume":"28","author":"KA Lee","year":"2022","unstructured":"Lee KA et al (2022) Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med 28(3):535\u2013544. https:\/\/doi.org\/10.1038\/s41591-022-01695-5","journal-title":"Nat Med"},{"issue":"10","key":"1072_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.ccell.2021.08.006","volume":"39","author":"N Cullin","year":"2021","unstructured":"Cullin N, Azevedo Antunes C, Straussman R, Stein-Thoeringer CK, Elinav E (2021) Microbiome and cancer. Cancer Cell 39(10):1317\u20131341. https:\/\/doi.org\/10.1016\/j.ccell.2021.08.006","journal-title":"Cancer Cell"},{"issue":"5","key":"1072_CR30","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1053\/j.gastro.2018.12.019","volume":"156","author":"CL Hvas","year":"2019","unstructured":"Hvas CL et al (2019) Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent clostridium difficile infection. Gastroenterology 156(5):1324\u20131332.e3 https:\/\/doi.org\/10.1053\/j.gastro.2018.12.019","journal-title":"Gastroenterology"},{"issue":"6161","key":"1072_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida N et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342(6161):967\u2013970. https:\/\/doi.org\/10.1126\/science.1240527","journal-title":"Science"},{"issue":"6264","key":"1072_CR32","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A et al (2015) Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084\u20131089. https:\/\/doi.org\/10.1126\/science.aac4255","journal-title":"Science"},{"issue":"6264","key":"1072_CR33","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079\u20131084. https:\/\/doi.org\/10.1126\/science.aad1329","journal-title":"Science"},{"issue":"6371","key":"1072_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"issue":"6371","key":"1072_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"issue":"6371","key":"1072_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V et al (2018) The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients. Science 359(6371):104\u2013108. https:\/\/doi.org\/10.1126\/science.aao3290","journal-title":"Science"},{"issue":"4","key":"1072_CR37","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","volume":"178","author":"E Riquelme","year":"2019","unstructured":"Riquelme E et al (2019) Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178(4):795\u2013806.e12. https:\/\/doi.org\/10.1016\/j.cell.2019.07.008","journal-title":"Cell"},{"issue":"6564","key":"1072_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.abf8403","volume":"374","author":"N Pernigoni","year":"2021","unstructured":"Pernigoni N et al (2021) Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science 374(6564):216\u2013224. https:\/\/doi.org\/10.1126\/science.abf8403","journal-title":"Science"},{"issue":"1","key":"1072_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41564-024-01890-9","volume":"10","author":"X Wang","year":"2025","unstructured":"Wang X et al (2025) Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice. Nat Microbiol 10(1):169\u2013184. https:\/\/doi.org\/10.1038\/s41564-024-01890-9","journal-title":"Nat Microbiol"},{"issue":"6529","key":"1072_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D et al (2021) Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371(6529):595\u2013602. https:\/\/doi.org\/10.1126\/science.abf3363","journal-title":"Science"},{"issue":"6529","key":"1072_CR41","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN et al (2021) Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371(6529):602\u2013609. https:\/\/doi.org\/10.1126\/science.abb5920","journal-title":"Science"},{"issue":"8","key":"1072_CR42","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","volume":"32","author":"Y Kim","year":"2024","unstructured":"Kim Y et al (2024) Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe 32(8):1380\u20131393e9. https:\/\/doi.org\/10.1016\/j.chom.2024.06.010","journal-title":"Cell Host Microbe"},{"issue":"8","key":"1072_CR43","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy B et al (2023) Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: A phase I trial. Nat Med 29(8):2121\u20132132. https:\/\/doi.org\/10.1038\/s41591-023-02453-x","journal-title":"Nat Med"},{"issue":"8","key":"1072_CR44","doi-asserted-by":"publisher","first-page":"e012659","DOI":"10.1136\/jitc-2025-012659","volume":"13","author":"DK Hadi","year":"2025","unstructured":"Hadi DK et al (2025) Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial. J Immunother Cancer 13(8):e012659. https:\/\/doi.org\/10.1136\/jitc-2025-012659","journal-title":"J Immunother Cancer"},{"key":"1072_CR45","doi-asserted-by":"publisher","first-page":"103025","DOI":"10.1016\/j.ctrv.2025.103025","volume":"140","author":"D van den Wekking","year":"2025","unstructured":"Wekking D, van den Ende T, Bijlsma MF, Vidal-Itriago A, Nieuwdorp M, van Laarhoven HWM (2025) Fecal microbiota transplantation to enhance cancer treatment outcomes across different cancer types: A systematic literature review. Cancer Treat Rev 140:103025. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103025","journal-title":"Cancer Treat Rev"},{"key":"1072_CR46","doi-asserted-by":"publisher","unstructured":"Porcari S et al (2026) Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-04189-2","DOI":"10.1038\/s41591-025-04189-2"},{"key":"1072_CR47","doi-asserted-by":"publisher","unstructured":"Fernandes R et al (2026) Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial. Nat Med 1\u201312. https:\/\/doi.org\/10.1038\/s41591-025-04183-8","DOI":"10.1038\/s41591-025-04183-8"},{"key":"1072_CR48","doi-asserted-by":"publisher","unstructured":"Duttagupta S et al (2026) Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nat Med 1\u201314. https:\/\/doi.org\/10.1038\/s41591-025-04186-5","DOI":"10.1038\/s41591-025-04186-5"},{"issue":"6285","key":"1072_CR49","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1126\/science.aad8852","volume":"352","author":"SS Li","year":"2016","unstructured":"Li SS et al (2016) Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 352(6285):586\u2013589. https:\/\/doi.org\/10.1126\/science.aad8852","journal-title":"Science"},{"issue":"9","key":"1072_CR50","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nrgastro.2016.98","volume":"13","author":"A Khoruts","year":"2016","unstructured":"Khoruts A, Sadowsky MJ (2016) Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 13(9):508\u2013516. https:\/\/doi.org\/10.1038\/nrgastro.2016.98","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"1072_CR51","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/2159-8290.CD-24-0066","volume":"14","author":"IC Glitza","year":"2024","unstructured":"Glitza IC et al (2024) Randomized placebo-controlled, biomarker-stratified phase ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity. Cancer Discov 14(7):1161\u20131175. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0066","journal-title":"Cancer Discov"},{"issue":"6575","key":"1072_CR52","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer CN et al (2021) Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632\u20131640. https:\/\/doi.org\/10.1126\/science.aaz7015","journal-title":"Science"},{"issue":"5","key":"1072_CR53","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cancers13050957","volume":"13","author":"Y Yoon","year":"2021","unstructured":"Yoon Y, Kim G, Jeon B-N, Fang S, Park H (2021) Bifidobacterium strain-specific enhances the efficacy of cancer therapeutics in tumor-bearing mice. Cancers 13(5):957. https:\/\/doi.org\/10.3390\/cancers13050957","journal-title":"Cancers"},{"issue":"4","key":"1072_CR54","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N et al (2022) Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 28(4):704\u2013712. https:\/\/doi.org\/10.1038\/s41591-022-01694-6","journal-title":"Nat Med"},{"issue":"9","key":"1072_CR55","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","volume":"30","author":"H Ebrahimi","year":"2024","unstructured":"Ebrahimi H et al (2024) Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 30(9):2576\u20132585. https:\/\/doi.org\/10.1038\/s41591-024-03086-4","journal-title":"Nat Med"},{"issue":"10","key":"1072_CR56","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.ccell.2025.07.012","volume":"43","author":"M Xie","year":"2025","unstructured":"Xie M et al (2025) Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. Cancer Cell 43(10):1885\u20131901.e10. https:\/\/doi.org\/10.1016\/j.ccell.2025.07.012","journal-title":"Cancer Cell"},{"issue":"10","key":"1072_CR57","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.chom.2021.08.001","volume":"29","author":"A Montalban-Arques","year":"2021","unstructured":"Montalban-Arques A et al (2021) Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe 29(10):1573\u20131588e7. https:\/\/doi.org\/10.1016\/j.chom.2021.08.001","journal-title":"Cell Host Microbe"},{"issue":"3","key":"1072_CR58","doi-asserted-by":"publisher","first-page":"115357","DOI":"10.1016\/j.celrep.2025.115357","volume":"44","author":"E Katkeviciute","year":"2025","unstructured":"Katkeviciute E et al (2025) Bacteria-derived 3-hydroxydodecanoic acid induces a potent anti-tumor immune response via the GPR84 receptor. Cell Rep 44(3):115357. https:\/\/doi.org\/10.1016\/j.celrep.2025.115357","journal-title":"Cell Rep"},{"issue":"6","key":"1072_CR59","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.annonc.2023.02.011","volume":"34","author":"A Spreafico","year":"2023","unstructured":"Spreafico A et al (2023) First-in-class microbial ecosystem therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Ann Oncol Off J Eur Soc Med Oncol 34(6):520\u2013530. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"1072_CR60","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cmet.2022.02.010","volume":"34","author":"H Wang","year":"2022","unstructured":"Wang H et al (2022) The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab 34(4):581\u2013594.e8. https:\/\/doi.org\/10.1016\/j.cmet.2022.02.010","journal-title":"Cell Metab"},{"key":"1072_CR61","doi-asserted-by":"publisher","first-page":"eabn0704","DOI":"10.1126\/sciimmunol.abn0704","volume":"7","author":"G Mirji","year":"2022","unstructured":"Mirji G et al (2022) The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci Immunol 7:eabn0704. https:\/\/doi.org\/10.1126\/sciimmunol.abn0704","journal-title":"Sci Immunol"},{"issue":"4","key":"1072_CR62","doi-asserted-by":"publisher","first-page":"101488","DOI":"10.1016\/j.xcrm.2024.101488","volume":"5","author":"Y Ma","year":"2024","unstructured":"Ma Y et al (2024) Intratumor microbiome-derived butyrate promotes lung cancer metastasis. Cell Rep Med 5(4):101488. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101488","journal-title":"Cell Rep Med"},{"issue":"7950","key":"1072_CR63","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05728-y","volume":"615","author":"J Tintelnot","year":"2023","unstructured":"Tintelnot J et al (2023) Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615(7950):168\u2013174. https:\/\/doi.org\/10.1038\/s41586-023-05728-y","journal-title":"Nature"},{"issue":"6","key":"1072_CR64","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.chom.2025.05.004","volume":"33","author":"X Ding","year":"2025","unstructured":"Ding X et al (2025) Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. Cell Host Microbe 33(6):941\u2013956.e10. https:\/\/doi.org\/10.1016\/j.chom.2025.05.004","journal-title":"Cell Host Microbe"},{"issue":"6","key":"1072_CR65","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/procel\/pwae005","volume":"15","author":"W Ma","year":"2024","unstructured":"Ma W et al (2024) Microbiota enterotoxigenic bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1. Protein Cell 15(6):419\u2013440. https:\/\/doi.org\/10.1093\/procel\/pwae005","journal-title":"Protein Cell"},{"key":"1072_CR66","doi-asserted-by":"publisher","first-page":"eadn9879","DOI":"10.1126\/sciimmunol.adn9879","volume":"9","author":"F Li","year":"2024","unstructured":"Li F et al (2024) Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms. Sci Immunol 9:eadn9879. https:\/\/doi.org\/10.1126\/sciimmunol.adn9879","journal-title":"Sci Immunol"},{"issue":"1","key":"1072_CR67","doi-asserted-by":"publisher","first-page":"12506","DOI":"10.1038\/s41598-023-39365-2","volume":"13","author":"S Tumas","year":"2023","unstructured":"Tumas S et al (2023) Engineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy. Sci Rep 13(1):12506. https:\/\/doi.org\/10.1038\/s41598-023-39365-2","journal-title":"Sci Rep"},{"issue":"8038","key":"1072_CR68","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41586-024-08033-4","volume":"635","author":"A Redenti","year":"2024","unstructured":"Redenti A et al (2024) Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature 635(8038):453\u2013461. https:\/\/doi.org\/10.1038\/s41586-024-08033-4","journal-title":"Nature"},{"issue":"10","key":"1072_CR69","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1021\/acssynbio.1c00097","volume":"10","author":"J Hyun","year":"2021","unstructured":"Hyun J et al (2021) Engineered attenuated salmonella typhimurium expressing neoantigen has anticancer effects. ACS Synth Biol 10(10):2478\u20132487. https:\/\/doi.org\/10.1021\/acssynbio.1c00097","journal-title":"ACS Synth Biol"},{"issue":"1","key":"1072_CR70","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/1078-0432.CCR-20-2065","volume":"27","author":"F Janku","year":"2021","unstructured":"Janku F et al (2021) Intratumoral injection of clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 27(1):96\u2013106. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2065","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1072_CR71","doi-asserted-by":"publisher","unstructured":"Nelson BE et al (2025) Phase Ib study of pembrolizumab in combination with intratumoral injection of clostridium novyi-NT in patients with advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3952","DOI":"10.1158\/1078-0432.CCR-24-3952"},{"issue":"1","key":"1072_CR72","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41467-023-37225-1","volume":"14","author":"X Ma","year":"2023","unstructured":"Ma X et al (2023) Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field. Nat Commun 14(1):1606. https:\/\/doi.org\/10.1038\/s41467-023-37225-1","journal-title":"Nat Commun"},{"issue":"11","key":"1072_CR73","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41551-021-00749-2","volume":"5","author":"K Han","year":"2021","unstructured":"Han K et al (2021) Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel. Nat Biomed Eng 5(11):1377\u20131388. https:\/\/doi.org\/10.1038\/s41551-021-00749-2","journal-title":"Nat Biomed Eng"},{"issue":"6510","key":"1072_CR74","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager LF et al (2020) Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369(6510):1481\u20131489. https:\/\/doi.org\/10.1126\/science.abc3421","journal-title":"Science"},{"issue":"10","key":"1072_CR75","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","volume":"42","author":"X Wang","year":"2024","unstructured":"Wang X et al (2024) Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell 42(10):1729\u20131746e8. https:\/\/doi.org\/10.1016\/j.ccell.2024.08.019","journal-title":"Cancer Cell"},{"issue":"24","key":"1072_CR76","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1158\/0008-5472.CAN-22-0455","volume":"82","author":"LM Chambers","year":"2022","unstructured":"Chambers LM et al (2022) Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer. Cancer Res 82(24):4654\u20134669. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0455","journal-title":"Cancer Res"},{"issue":"1","key":"1072_CR77","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1038\/s41467-021-24331-1","volume":"12","author":"M Luu","year":"2021","unstructured":"Luu M et al (2021) Microbial short-chain fatty acids modulate CD8\u2009+\u2009T cell responses and improve adoptive immunotherapy for cancer. Nat Commun 12(1):4077. https:\/\/doi.org\/10.1038\/s41467-021-24331-1","journal-title":"Nat Commun"},{"issue":"11","key":"1072_CR78","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.ccell.2023.09.012","volume":"41","author":"LE Colbert","year":"2023","unstructured":"Colbert LE et al (2023) Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell 41(11):1945\u20131962e11. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.012","journal-title":"Cancer Cell"},{"issue":"1","key":"1072_CR79","doi-asserted-by":"publisher","first-page":"2530157","DOI":"10.1080\/19490976.2025.2530157","volume":"17","author":"Y Morsy","year":"2025","unstructured":"Morsy Y et al (2025) Blood-borne immune cells carry low biomass DNA remnants of microbes in patients with colorectal cancer or inflammatory bowel disease. Gut Microbes 17(1):2530157. https:\/\/doi.org\/10.1080\/19490976.2025.2530157","journal-title":"Gut Microbes"},{"key":"1072_CR80","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fcimb.2019.00148","volume":"9","author":"DJ Castillo","year":"2019","unstructured":"Castillo DJ, Rifkin RF, Cowan DA, Potgieter M (2019) The Healthy Human Blood Microbiome: Fact or Fiction? Front Cell Infect Microbiol 9:148. https:\/\/doi.org\/10.3389\/fcimb.2019.00148","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"1072_CR81","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.ccell.2023.08.012","volume":"41","author":"N-N Liu","year":"2023","unstructured":"Liu N-N et al (2023) The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell 41(11):1927\u20131944e. https:\/\/doi.org\/10.1016\/j.ccell.2023.08.012","journal-title":"Cancer Cell"},{"issue":"7827","key":"1072_CR82","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-020-2541-0","volume":"586","author":"E Kadosh","year":"2020","unstructured":"Kadosh E et al (2020) The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature 586(7827):133\u2013138. https:\/\/doi.org\/10.1038\/s41586-020-2541-0","journal-title":"Nature"},{"issue":"6516","key":"1072_CR83","doi-asserted-by":"publisher","first-page":"eaay9097","DOI":"10.1126\/science.aay9097","volume":"370","author":"H Guo","year":"2020","unstructured":"Guo H et al (2020) Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. Science 370(6516):eaay9097. https:\/\/doi.org\/10.1126\/science.aay9097","journal-title":"Science"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-026-01072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-026-01072-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-026-01072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:22:41Z","timestamp":1792160561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-026-01072-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1072"],"URL":"https:\/\/doi.org\/10.1007\/s00281-026-01072-1","relation":{},"ISSN":["1863-2300"],"issn-type":[{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MS has shares and is co-founder of Recolony\/Adaluria AG, Zurich, CH and has shares in PharmaBiome AG, Zurich, CH. MS served as Advisor for Abbvie, Gilead, Fresenius, Topadur, Takeda, Roche, Astra Zeneca, Pileje and Celltrion. MS received speaker\u2019s honoraria from Janssen, Falk Pharma, Vifor Pharma, Pileje, Institut Allergosan and Bromatech. MS received research grants from Abbvie, Takeda, Gilead, Gnubiotics, Roche, Axalbion, Pharmabiome, Topadur, Basilea, MBiomics, Storm Therapeutics, LimmatTech, Zealand Pharma, NodThera, Calypso Biotech, Menarini, Pileje, Herbodee, Vifor. The other authors declare no conflict of interest","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"5"}}